Search Results | Cancer Research | American Association for Cancer Research

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Abstract CT035: Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer

Olivier Rixe, Vincent Castonguay, Henry Conter, Eva Chalas, Pratibha Desai, Christian Squillante, Lisa A. MacDonald, Rebekah Conlon, Yogesh Bramhecha, Heather Hirsch, Jeremy R. Graff, Stephan Fiset

Cancer Res (2022) 82 (12_Supplement): CT035.

DOI: https://doi.org/10.1158/1538-7445.AM2022-CT035

Published: 15 June 2022

View article

Journal Articles

Abstract 3767: Imprime PGG, a soluble yeast b-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing

Kathryn A. Fraser, Takashi Kangas, Ross B. Fulton, Steven M. Leonardo, Ben Harrison, Yumi Yokoyama, Nandita Bose, Jeremy R. Graff, Mark Uhlik, Keith B. Gorden

Cancer Res (2018) 78 (13_Supplement): 3767.

DOI: https://doi.org/10.1158/1538-7445.AM2018-3767

Published: 01 July 2018

View article

Journal Articles

Abstract 1703: A novel tumor vaccine platform: direct conjugation of antigens to the β glucan PAMP Imprime PGG enhances antigen presentation and T cell priming

Kyle S. Michel, Ross B. Fulton, Steven M. Leonardo, Keith B. Gorden, Jeremy R. Graff, Michael E. Danielson

Cancer Res (2017) 77 (13_Supplement): 1703.

DOI: https://doi.org/10.1158/1538-7445.AM2017-1703

Published: 01 July 2017

View article

Journal Articles

Abstract 3919: Phosphorylation of eIF4E is a critical factor in development and progression of breast cancer in women

Chad A. Dumstorf, Larry E. Douglass, James A. Deddens, Thomas G. Lewis, Kyle Darpel, Christian Gausvik, Jeremy R. Graff, Julia H. Carter

Cancer Res (2016) 76 (14_Supplement): 3919.

DOI: https://doi.org/10.1158/1538-7445.AM2016-3919

Published: 15 July 2016

View article

Journal Articles

Abstract LB-080: Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern) activates the direct killing functions of innate immune cells in concert with tumor targeting antibodies

Steven M. Leonardo, Ross B. Fulton, Keith B. Gorden, Katy Fraser, Ben Harrison, Takashi Kangas, Adria Jonas, Yumi Yokoyama, Nadine Ottoson, Nandita Bose, Jeremy R. Graff

Cancer Res (2016) 76 (14_Supplement): LB-080.

DOI: https://doi.org/10.1158/1538-7445.AM2016-LB-080

Published: 15 July 2016

View article

Journal Articles

Abstract LB-087: Imprime PGG drives adaptive immune resistance within the tumor microenvironment by modulating the myeloid compartment and enhances the efficacy of anti-PD1 antibody in vivo

Adria L. Bykowski Jonas, Anissa SH Chan, Nadine R. Ottoson, Xiaohong Qiu, Kathryn Fraser, Takashi O. Kangas, Ross Fulton, Blaine Rathmann, Jeremy R. Graff, Nandita Bose

Cancer Res (2016) 76 (14_Supplement): LB-087.

DOI: https://doi.org/10.1158/1538-7445.AM2016-LB-087

Published: 15 July 2016

View article

Journal Articles

Abstract LB-089: Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern), effectively elicits in vivo maturation of antigen presenting cells in mice and humans, suggesting potential synergy with checkpoint inhibitor therapy

Ross B. Fulton, Steven M. Leonardo, Adria B. Jonas, Kathryn A. Fraser, Anissa S.H. Chan, Nadine R. Ottoson, Michael E. Danielson, Nandita Bose, Jeremy R. Graff, Keith Gorden

Cancer Res (2016) 76 (14_Supplement): LB-089.

DOI: https://doi.org/10.1158/1538-7445.AM2016-LB-089

Published: 15 July 2016

View article

Journal Articles

Abstract LB-228: Imprime PGG treatment elicits a coordinated antitumor immune response that triggers enhanced expression of PD-L1 on tumor cells as well as monocyte-derived macrophages and dendritic cells

Nandita Bose, Anissa SH Chan, Adria Jonas, Xiaohong Qiu, Nadine R. Ottoson, Takashi Kangas, Jeremy R. Graff

Cancer Res (2015) 75 (15_Supplement): LB-228.

DOI: https://doi.org/10.1158/1538-7445.AM2015-LB-228

Published: 01 August 2015

View article

Journal Articles

Abstract A28: Eukaryotic initiation factor 4E phosphorylation in human malignant melanoma

Julia H. Carter, Reed Spaulding, James A. Deddens, Bruce M. Colligan, Grant Lewis, Jackson O. Pemberton, Jeremy R. Graff, Larry E. Douglass

Cancer Res (2015) 75 (14_Supplement): A28.

DOI: https://doi.org/10.1158/1538-7445.MEL2014-A28

Published: 16 July 2015

View article

Journal Articles

Abstract LB-302: eIF4E phosphorylation is Mnk-dependent but does not require assembly of the eIF4F translation initiation complex

Chad Hall, Chad Dumstorf, Bruce Konicek, Nathaniel Robichaud, Ann McNulty, Steve Parsons, Jerry Pelltier, Nahum Sonenberg, Jeremy R. Graff

Cancer Res (2014) 74 (19_Supplement): LB-302.

DOI: https://doi.org/10.1158/1538-7445.AM2014-LB-302

Published: 01 October 2014

View article

Journal Articles

Abstract 4403: Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models

Sau-Chi Betty Yan, Suzane L. Um, Victoria L. Peek, Megan N. Thobe, Kelly M. Credille, Jennifer R. Stephens, Jason R. Manro, Darryl W. Ballard, Jessica A. Baker, Joel D. Cook, Bruce W. Konicek, Jeremy R. Graff, Timothy R. Holzer, Richard A. Walgren

Cancer Res (2014) 74 (19_Supplement): 4403.

DOI: https://doi.org/10.1158/1538-7445.AM2014-4403

Published: 01 October 2014

View article

Journal Articles

Abstract 3042: LY2801653: An orally bioavailable MET kinase inhibitor with inhibitory activity against the oncoproteins ROS1 and MKNK1/2.

Sau-Chi B. Yan, Megan N. Thobe, Bruce W. Konicek, Victoria L. Peek, Suzane L. Um, Richard A. Walgren, Huaxing Pei, Timothy P. Burkholder, Jeremy R. Graff

Cancer Res (2013) 73 (8_Supplement): 3042.

DOI: https://doi.org/10.1158/1538-7445.AM2013-3042

Published: 15 April 2013

View article

Journal Articles

Abstract 2339: Prevalence of MET expression, activating mutations of KRAS and IDH1/2, and ROS1 fusions in cholangiocarcinoma patient tumor samples.

Cancer Res (2013) 73 (8_Supplement): 2339.

DOI: https://doi.org/10.1158/1538-7445.AM2013-2339

Published: 15 April 2013

View article

Journal Articles

Abstract LB-235: Sensitivity of diffuse large B cell lymphoma cells to Enzastaurin (LY317615.HCl) and its primary metabolite (LY326020) is critically dependent upon disruption of the eIF4F translation initiation complex

Ann M. McNulty, Chad A. Dumstorf, Chad A. Dumstorf, Stephen H. Parsons, Bruce W. Konicek, Chad A. Hall, Jeremy R. Graff

Cancer Res (2012) 72 (8_Supplement): LB-235.

DOI: https://doi.org/10.1158/1538-7445.AM2012-LB-235

Published: 15 April 2012

View article

Journal Articles

Abstract LB-384: Elevated eIF4E phosphorylation is associated with advanced malignancy and decreased patient survival and can be therapeutically inhibited by a novel, orally bio-available Mnk inhibitor

Jeremy R. Graff, Bruce Konicek, Chad Dumstorf, Stefan Siwko, Bruce Colligan, James A. Deddens, Larry Douglass, Julia H. Carter

Cancer Res (2011) 71 (8_Supplement): LB-384.

DOI: https://doi.org/10.1158/1538-7445.AM2011-LB-384

Published: 15 April 2011

View article

Journal Articles

Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases

Bruce W. Konicek, Jennifer R. Stephens, Ann M. McNulty, Nathaniel Robichaud, Robert B. Peery, Chad A. Dumstorf, Michele S. Dowless, Philip W. Iversen, Stephen Parsons, Karen E. Ellis, Denis J. McCann, Jerry Pelletier, Luc Furic, Jonathan M. Yingling, Louis F. Stancato, Nahum Sonenberg, Jeremy R. Graff

Cancer Res (2011) 71 (5): 1849–1857.

DOI: https://doi.org/10.1158/0008-5472.CAN-10-3298

Published: 01 March 2011

View article

Journal Articles

Abstract 1183: Association of germline variants of the TGFβR1 gene in colorectal cancer patients

James P. Schaeper, Kevin Murray, Jessica L. DeBrosse, Briana Vogt, Denise Lucas, Bruce M. Colligan, James A. Deddens, Larry E. Douglass, Jeremy R. Graff, Julia H. Carter

Cancer Res (2010) 70 (8_Supplement): 1183.

DOI: https://doi.org/10.1158/1538-7445.AM10-1183

Published: 15 April 2010

View article

Journal Articles

eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival

Jeremy R. Graff, Bruce W. Konicek, Rebecca L. Lynch, Chad A. Dumstorf, Michele S. Dowless, Ann M. McNulty, Stephen H. Parsons, Leslie H. Brail, Bruce M. Colligan, Jonathan W. Koop, Bernadette M. Hurst, James A. Deddens, Blake L. Neubauer, Louis F. Stancato, Harry W. Carter, Larry E. Douglass, Julia H. Carter

Cancer Res (2009) 69 (9): 3866–3873.

DOI: https://doi.org/10.1158/0008-5472.CAN-08-3472

Published: 30 April 2009

View article

Includes: Supplementary data

Journal Articles

Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy

Jeremy R. Graff, Bruce W. Konicek, Julia H. Carter, Eric G. Marcusson

Cancer Res (2008) 68 (3): 631–634.

DOI: https://doi.org/10.1158/0008-5472.CAN-07-5635

Published: 01 February 2008

View article

Journal Articles

Enzastaurin (LY317615.HCl) suppresses signaling through the PKC and AKT pathways, inducing apoptosis, suppressing tumor-induced angiogenesis and reducing growth of human cancer xenografts

Ann M. McNulty, Bruce W. Konicek, Rebecca L. Lynch, Donald Thornton, Larry Douglass, Bruce Colligan, Julia H. Carter, Jeremy R. Graff

Cancer Res (2006) 66 (8_Supplement): 314–315.

Published: 15 April 2006

View article

NARROW

Abstract CT035: Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer

Abstract 3767: Imprime PGG, a soluble yeast b-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing

Abstract 1703: A novel tumor vaccine platform: direct conjugation of antigens to the β glucan PAMP Imprime PGG enhances antigen presentation and T cell priming

Abstract 3919: Phosphorylation of eIF4E is a critical factor in development and progression of breast cancer in women

Abstract LB-080: Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern) activates the direct killing functions of innate immune cells in concert with tumor targeting antibodies

Abstract LB-087: Imprime PGG drives adaptive immune resistance within the tumor microenvironment by modulating the myeloid compartment and enhances the efficacy of anti-PD1 antibody in vivo

Abstract LB-089: Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern), effectively elicits in vivo maturation of antigen presenting cells in mice and humans, suggesting potential synergy with checkpoint inhibitor therapy

Abstract LB-228: Imprime PGG treatment elicits a coordinated antitumor immune response that triggers enhanced expression of PD-L1 on tumor cells as well as monocyte-derived macrophages and dendritic cells

Abstract A28: Eukaryotic initiation factor 4E phosphorylation in human malignant melanoma

Abstract LB-302: eIF4E phosphorylation is Mnk-dependent but does not require assembly of the eIF4F translation initiation complex

Abstract 4403: Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models

Abstract 3042: LY2801653: An orally bioavailable MET kinase inhibitor with inhibitory activity against the oncoproteins ROS1 and MKNK1/2.

Abstract 2339: Prevalence of MET expression, activating mutations of KRAS and IDH1/2, and ROS1 fusions in cholangiocarcinoma patient tumor samples.

Abstract LB-235: Sensitivity of diffuse large B cell lymphoma cells to Enzastaurin (LY317615.HCl) and its primary metabolite (LY326020) is critically dependent upon disruption of the eIF4F translation initiation complex

Abstract LB-384: Elevated eIF4E phosphorylation is associated with advanced malignancy and decreased patient survival and can be therapeutically inhibited by a novel, orally bio-available Mnk inhibitor

Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases

Abstract 1183: Association of germline variants of the TGFβR1 gene in colorectal cancer patients

eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival

Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy

Enzastaurin (LY317615.HCl) suppresses signaling through the PKC and AKT pathways, inducing apoptosis, suppressing tumor-induced angiogenesis and reducing growth of human cancer xenografts

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only